Type II collagen (CII)-induced arthritis (CIA) in rats 1) and mice 2) has both clinical and histological similarities to human rheumatoid arthritis.
CII was dissolved overnight at 4°C in 0.1 M acetic acid at 2 mg/ml, after which the solution was emulsified in an equal volume of complete Freund's adjuvant (CFA). This emulsion containing 100 mg of CII was injected intradermally into the base of the tail, and the mice were given an intraperitoneal injection of the same emulsion 20 d later.
Clinical Assessment
7)
The clinical symptoms of arthritis in limbs were evaluated blindly with a visual scoring system every 4 d after day 20. Arthritic lesion of a limb was graded on a scale of 0-4: 0ϭno change, 1ϭswelling and erythema of the digit, 2ϭmild swelling and erythema of the limb, 3ϭgross swelling and erythema of the digit, 4ϭgross deformity and inability to use the limb. The arthritis score of each mouse was the sum of the scores of each of the limbs except the right hind limb, the maximum score being 12. A mouse that showed a score of 1 or more was regarded to be arthritic. The incidence and day of onset of arthritis also were recorded. The right hind paw's volume of each mouse was determined on days 0, 20, 24, 28, 32, 36 and 40 after 1st immunization with CII.
Measurement of Anti-CII Antibodies
On day 40, blood was collected from the mice, after which the serum level of IgG antibodies to CII was determined by the enzyme-linked immunosorbent assay (ELISA). Briefly a 100 ml sample of serum (1 : 2000) in phosphate-buffered saline (PBS) was added to the wells of a 96 well plate that had been coated with CII overnight at 4°C. The plate was incubated for 2 h at room temperature then, after the washing of the wells with PBS, an addition was made of 100 ml goat antimouse IgG (1 : 400) in PBS Ϫ . After incubation for 1 h at room temperature, the wells were washed with PBS Ϫ , after which 100 ml of 0.05% o-phenylenediamine was added. After incubation for 1 h at room temperature, the reaction was stopped by the addition of 50 ml of 4 N H 2 SO 4 . Color was allowed to develop for 30 min, then the optical density was measured at 490 nm.
Measurement of the Delayed-Type Skin Reaction to CII 7)
The delayed-type hypersensitivity (DTH) reaction to CII was assessed by the mouse ear skin test. Briefly, on day 40, 20 ml of 0.2% CII solution in 0.1 mol/l acetic acid was injected intradermally into the right ear. The thickness of the ear was measured under ether anesthesia with a micrometer just before and 24 h after injection of the CII solution. A difference between the two values was regarded as reflecting edema induced by the DTH reaction.
Statistical Analysis All results were expressed as meanϮS.E.M. and they were analyzed for significance by means of the Student's t-test. Differences were accepted as statistically significant at pϽ0.05.
RESULTS

Effect of ITE on Clinical Assessment of CIA
The incidence of arthritis in control group was 91.7%, the mean onset occurring 25.5Ϯ5.4 d after the 1st immunization with CII (Table 1) . ITE had no effect on the onset of arthritis but did decrease the incidence rate of arthritis (Table 1) . And ITE lowered the arthritis score at 150 to 600 mg/kg (Fig. 2) . Throughout the experiments, there were no statistical differences between the body weight in ITE-treated groups and that in arthritis control group (data not shown).
Effect of ITE on the Development of Paw Edema of CIA Figure 3 shows the volume change of mice's hind paw. In control mice, paw volume began to increase on day 28, with a peak effect on day 36. Treatment with ITE or IB significantly reduced the development of paw edema.
Effect of ITE on the Concentration of Serum Antibodies to CII A significant elevation of serum antibodies to CII was found in the arthritis control mice. ITE had no effect on the concentration of these antibodies (data not shown).
Effect of ITE on Delayed-Type Skin Reaction to CII The gain in ear thickness for the arthritis control mice was 0.15Ϯ0.07 mm 24 h after challenge with an intradermal injection of CII (Table 2 ). ITE at 600 mg/kg significantly suppressed the delayed-type skin reaction (Table 2 ).
DISCUSSION
The induction of immunological reactivity to CII, a major component of cartilage, has been used to establish an experimental model of arthritis in the rat.
1) Mice were injected with CII emulsified in CFA, in experimental conditions similar to those known to be effective in the rat. 2, 3) This model has been widely used to evaluate antiarthritic drugs. But not all antirheumatic drugs have similar effects on murine CIA. Auranofin 9) and D-penicillamine 10) increase the severity of the arthritis and/or accelerate its onset. Lobenzarit 11) is not effective in CIA model.
Using the murine CIA model, the antiarthritic effect of ITE, a newly developed anti-inflammatory drug, was evaluated. In the clinical assessment, ITE significantly lowered the arthritis score and inhibited the arthritic swelling of a hind paw.
To clarify the mechanism of ITE, we studied the effect of the drug on humoral and cellular immunity to CII in CIA mice. As CIA can be passively transferred by sera from donors immunized with CII, anti-CII antibodies function in the initiation of arthritis. [12] [13] [14] ITE had no effect on the serum level of anti-CII antibodies. But ITE at 600 mg/kg significantly suppressed the delayed-type skin reation to CII in CIA mice. Therefore ITE is believed to inhibit murine CIA through suppression of cell-mediated immune responses to CII.
